Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence–TIMI 73b Imaging Study

Despite substantial triglyceride and remnant cholesterol lowering, treatment with olezarsen for 12 months on top of standard-of-care lipid-lowering therapy in patients with largely moderate hypertriglyceridemia did not affect noncalcified coronary plaque volume.